This is the authors' abstract. We don't add key points for this paper.
The involvement of a humoral factor (named as haemopoietin) in the regulation of haematopoiesis, was firstly described in literature in 1906 A link between erythropoietin (EPO) and erythropoiesis was described 40 years later In 1977, EPO was purified from urine collected from patients suffering from aplastic anaemia [4], the nucleotide sequence of human EPO gene was determined in 1985 and the cloning and expression of the gene led to the production of recombinant human EPO (rhEPO) The first clinical trial using rhEPO in the treatment of the anaemia of end-stage renal failure was published in 1987 Since then, many therapeutic trials have been developed to demonstrate the potential use of rhEPO in the treatment of different kinds of anaemia, namely associated with prematurity, AIDS, malignancies, congestive heart failure, post chemotherapy and post transplantation
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Elisio M. Costa (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: